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Abstract
Summary In a population-based study of older Swedish women, we investigated the proportion of women treated with osteo-
porosis medication in relation to the proportion of women eligible for treatment according to national guidelines. We found that
only a minority (22%) of those eligible for treatment were prescribed osteoporosis medication.
Introduction Fracture rates increase markedly in old age and the incidence of hip fracture in Swedish women is among the highest
in the world. Although effective pharmacological treatment is available, treatment rates remain low. Limited data are available
regarding treatment rates in relation to fracture risk in a population-based setting in older women. Therefore, we aimed to investigate
the proportion of older women eligible for treatment according to Swedish Osteoporosis Society (SvOS) guidelines.
Methods A population-based study was performed in Gothenburg in 3028 older women (77.8 ± 1.6 years [mean ± SD]). Bone
mineral density of the spine and hip was measured with dual-energy X-ray absorptiometry. Clinical risk factors for fracture and
data regarding osteoporosis medication was collected with self-administered questionnaires. Logistic regression was used to
evaluate whether the 10-year probability of sustaining a major osteoporotic fracture (FRAX-score) or its components predicted
treatment with osteoporosis medication.
Results For the 2983 women with complete data, 1107 (37%) women were eligible for treatment using SvOS criteria. The
proportion of these women receiving treatment was 21.8%. For women eligible for treatment according to SvOS guidelines,
strong predictors for receiving osteoporosis medication were glucocorticoid treatment (odds ratio (95%CI) 2.88 (1.80–4.59)) and
prior fracture (2.58 (1.84–3.61)).
Conclusion This study demonstrates that a substantial proportion of older Swedish women should be considered for osteoporosis
medication given their high fracture risk, but that only a minority receives treatment.
Keywords Bone fracture . Osteoporosis . Risk assessment . Therapeutics
Introduction
Osteoporosis is a disease characterized by low bone mineral
density and structural decay, which increases the risk of
fracture [1]. Fractures result in great patient suffering, negative
effects on quality of life and increased mortality, especially
after hip fracture, and high financial costs [2, 3]. In 2010, three
and a half million osteoporosis-related fractures occurred in
the EU at an annual cost of 37 billion euros [4]. The number of
fractures is expected to rise and by 2025, the estimated num-
ber is four and a half million fractures to a cost of 46.8 billion
euros annually [4]. Fracture rates increase markedly with age
and the incidence of hip fracture in Swedish women is among
the highest in the world [5]. Although effective pharmacolog-
ical treatment is available [6], treatment rates in Sweden re-
main low even for older patients with prevalent fracture [7, 8].
Only limited data are available regarding treatment rates in
relation to a thoroughly evaluated fracture risk in a
population-based setting in older women [9].
Eligibility for treatment varies in different countries.
Relevant criteria include the presence of osteoporosis at one
or more densitometric site, prior fracture (particularly spine,
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hip, or multiple fractures), and high fracture probabilities.
Irrespective of the criteria used, the uptake of bone-specific
treatment is low [10, 11]. A large Danish register study found
that only a small fraction of the expected number of women
with osteoporosis were diagnosed and that very few women
with fractures received osteoporosis medication after age
50 years [10, 11]. Studies from Germany and the US have
shown that only 21.7% and 28.6% of patients with diagnosed
osteoporosis received an osteoporosis medication, respective-
ly [10, 11].
Common barriers for not being treated are fear of potential
side effects, such as gastro-intestinal events [12], and rare side
effects, such as atypical femur fractures and osteonecrosis of
the jaw [13], as well as costs of osteoporosis evaluations and
medications [14].
Factors associated with receiving osteoporosis medication
are partly driven by characteristics such as a diagnosis of
osteoporosis and osteopenia as well as hip, spine, and multiple
fractures [15, 16].
The fracture risk calculation tool FRAX® is recommended
in many clinical guidelines to calculate the absolute 10-year
probability of major osteoporosis and hip fracture [17], based
on clinical risk factors and bone mineral density (BMD) [18].
FRAX has been incorporated in the guidelines issued by the
American National Osteoporosis Foundation (NOF), the
National Osteoporosis Guideline Group (NOGG), and the
Swedish Osteoporosis society (SvOS). The incorporation of
FRAX into treatment guidelines emphasizes a substantial
need for osteoporosis medication in the elderly, in whom a
very small minority currently receives treatment in the
United States (US) [19, 20].
The aim of this study was to investigate the proportion of
older Swedish women eligible for treatment according to the
SvOS guidelines, and to determine whether factors could be
identified that predicted prescription of osteoporosis medica-
tion. As a sensitivity analysis, we also aimed to determine the
treatment gap if the NOF and NOGG guidelines were to be
applied to this Swedish population of older women.
Methods
Subjects
A population-based, prospective study (Sahlgrenska
University hospital Prospective Evaluation of Risk of Bone
fractures—The SUPERB study) was based in Gothenburg,
Sweden. A national population register was used to identify
women aged 75 to 80 years, living within the greater
Gothenburg area. An initial manual screening was performed
based on home address, to ensure that the participants were
within the right age range and to exclude those residing in
special housing. The inclusion and exclusion criteria have
been described earlier [21, 22]. The study included 3028 el-
derly women. All womenwere first contacted by letter follow-
ed by telephone. The women eligible for the study were able
to walk, with or without aid, sign an informed consent, and
complete a questionnaire. To be able to include 3028 women,
6832 were contacted, of which 436 (6.4%) were excluded for
reasons such as bilateral hip replacement, unable to commu-
nicate in Swedish, or not able to walk with or without a walk-
ing aid. Of all women contacted who met the inclusion
criteria, 3368 (52.6%) declined to participate, giving an inclu-
sion rate of 47.4%.
Anthropometrics
Body height, measured with a standardized wall-mounted
stadiometer, was measured two consecutive times. If the two
height measurements differed by ≥ 5 mm, a third measure-
ment was performed. An average of the two height measure-
ments, alternatively the two most similar measurements if
three were obtained, was used. Body weight was measured
to the nearest 0.1 kg using the same scale in all women.
Risk factors and FRAX-score calculation
Other clinical risk factors, such as medical history, frac-
ture, living alone, level of education, falls the last
12 months, current smoking, parental history of hip frac-
ture, oral glucocorticoids for 3 months or more with
prednisolone 5 mg or equivalent, diabetes, rheumatoid
arthritis, and high alcohol consumption were assessed
by questionnaires. Self-reported fractures sustained after
the age of 50 years and at any location, except the skull
and face, were included in the FRAX-score calculations.
Current smoking was defined by validated questionnaire
[23]. A minority of participants (≈ 49; 1.6%) could not
recall if any parent had sustained a hip fracture. In these
cases, a null response was assumed. To define high al-
cohol consumption, a limit of 21 standard drinks per
week was used [24]. Medical history including prior
treatment for osteoporosis (current and previous use of
oral bisphosphonates (ongoing or within 2 years), zole-
dronic acid (ongoing or within 3 years), denosumab (on-
going or within 1 year), and teriparatide) was assessed
by questionnaires. Blood pressure was measured twice in
the right arm and an average of the two measurements
were used for both diastolic and systolic pressure. The
10-year probability for major osteoporotic fracture and
hip fracture (FRAX) was calculated using the Swedish
FRAX model with areal bone mineral density (aBMD)
of the femoral neck together with all clinical risk factors
except for secondary osteoporosis, which does not con-
tribute to the calculation of fracture risk when aBMD is
included.
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Dual-energy X-ray absorptiometry
Areal BMD of the hip and spine was measured by dual-energy
X-ray absorptiometry (DXA). One primary DXA-device,
Hologic Discovery A (S/N 86491) (Waltham, MA, USA),
was used to measure most participants (n = 2995). The
National Health and Nutrition Examination Survey
(NHANES) III reference database for femoral neck and total
hip in 20–29 year old Caucasian women as well as the
Hologic material for lumbar spine consisting of 30-year-old
Caucasian American women were used to calculate the corre-
sponding T-scores [25, 26]. Due to machine failure, a small
proportion of women (n = 33) was measured with another
Hologic Discovery A DXA device (Waltham, MA, USA).
The potential discrepancy between the two machines was tak-
en into account by performing a cross-calibration. This cross-
calibration study consisted of 31 women aged 76.3 ± 0.9 years
(only 30 women were available for the hip scan) measured
with both machines within a period of median 7 days (inter-
quartile range of 2.0–10.0 days for 31 individuals). Using a
linear regression, with the alternative machine as independent
variable and the study machine as dependent variable, a re-
gression equation was generated. The regression coefficient
and constant was 1.00 and 0.01 for femoral neck, 0.98 and
0.015 for total hip, and 1.021 and − 0.008 for lumbar spine.
Variable-specific equation was further used to adjust all
aBMD measurements obtained from the alternative machine.
Eligibility for treatment
NOF, NOGG, and SvOS guidelines were used to identify
subjects who were eligible for treatment. SvOS criteria [27]
included (1) previous hip or spine fracture, (2) osteoporosis,
(3) low BMD (T-score ≤ − 2.0 SD), other (than spine or hip)
prevalent fracture and a FRAX-score ≥ 20% for a MOF, or (4)
5 mg of daily oral glucocorticoid treatment > 3 months. NOF
criteria [28] included (1) diagnosis of osteoporosis at the
spine, femoral neck, or total hip, (2) osteopenia, in combina-
tion with a FRAX-score ≥ 20% for a MOF or ≥ 3% for a hip
fracture, and (3) self-reported hip or spine fracture. NOGG
criteria [29] included (1) prior fracture, (2) FRAX-score ≥
20% for a MOF, or (3) ongoing glucocorticoid treatment with
7.5 mg or more.
Statistical analyses
NOF, NOGG, and SvOS guidelines were used to identify
subjects who were eligible for treatment. Descriptive statistics
were used to report the proportion of women who fulfilled the
recommendations for treatment with regard to either NOF,
NOGG, or SvOS guidelines. All analyses were cross-section-
al. The means of continuous variables between groups were
compared with an independent samples t test. A chi-square
test was used to compare proportions. Backward stepwise
logistic regression analysis was performed to investigate fac-
tors that were associated with receiving osteoporosis treat-
ment. To evaluate these factors independently of each other,
a multivariate analysis was made. All statistical analyses were
performed using SPSS (version 24, SPSS, Inc., Chicago, IL,
USA) and a p value below 0.05 was considered significant.
Results
Characteristics
This study included 2983 women with sufficient data to de-
termine their eligibility for treatment with regard to either
SvOS, NOF, or NOGG guidelines. Women eligible for treat-
ment under either SvOS, NOF, or NOGG guidance were
older, shorter, had lower body weight, higher prevalence of
fracture, and lower BMD at the total hip and femoral neck
than women ineligible for. Women eligible for treatment,
using SvOS, NOF, and NOGG also had higher FRAX-
scores for both major osteoporotic fracture and hip fracture.
The proportion of current smokers were similar between the
two groups defined by SvOS-criteria. In contrast, women el-
igible for treatment according to NOF and NOGG-criteria had
a higher prevalence of smokers, while women without eligi-
bility for treatment, in all three groups, had a higher proportion
of diabetes (Table 1).
Treatment gap
From the total cohort of 2983 women, 1107 (37%) women
were eligible for treatment when applying the SvOS guide-
lines. For these women, only 241 (21.8%) had current or re-
cent osteoporosis medication (Fig. 1). Of the treated women,
the most common drugs were the oral bisphosphonates
(89.2%), followed by denosumab (9.1%), and zoledronic acid
(7.9%) (Fig. 1). From the included 2983 women studied, 2411
(81%) women were eligible for treatment when applying the
NOF-guidelines. Of these women, only 303 (12.6%) had cur-
rent or recent osteoporosis medication (Fig. 2). In the whole
cohort, 1698 (56.9%) womenwere eligible for treatment when
considering the NOGG guidelines. For these women, only
263 (15.5%) had current or recent osteoporosis medication
(Fig. 2). Seventy-four (23.5%) women who were not eligible
for treatment according to SvOS guidelines received osteopo-
rosis medication.
Variables associated with osteoporosis treatment
In the group of women eligible for treatment according to the
SvOS guidelines (n = 1107), 241 (21.8%) women in total had
reported current or recent osteoporosis treatment (Table 2).
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Women receiving treatment, more commonly had prior frac-
tures, glucocorticoid treatment (in doses equal to or higher
than 5 mg p.o. glucocorticoids for at least 3 months), and a
higher FRAX-score for major osteoporotic fracture than con-
trols. A smaller proportion of the treated women than the
untreated women had high blood pressure (Table 2).
Logistic regression was used to investigate which variables
were associated with receiving osteoporosis medication with-
in the SvOS-eligible women. In a univariate analysis, vari-
ables associated with increased odds ratio for osteoporosis
treatment were prior fracture (OR 2.21, CI 1.61–3.06),
glucocorticoid treatment (OR 2.13, CI 1.37–3.30), FRAX-
score with BMD for major osteoporotic fracture (OR 1.02
per % increase, CI 1.00–1.03), and FRAX-score with BMD
for hip fracture (OR 1.01 per % increase, CI 1.00–1.02)
(Table 3). Characteristics associated with a decreased odds
ratio of receiving osteoporosis medication was high blood
pressure (OR 0.66 per mm/Hg increase, CI 0.49–0.88)
(Table 3).
With a backward stepwise regression model, including all
variables except FRAX-score, the optimal model of predicting
osteoporosis treatment was designed from the following




















Age, years 77.7 ± 1.6 78.0 ± 1.6c 77.5 ± 1.6 77.8 ± 1.6c 77.6 ± 1.6 77.9 ± 1.6c
Height, cm 162.5 ± 5.7# 160.8 ± 6.2£c 163.4 ± 5.8€ 161.5 ± 5.9$c 162.4 ± 5.7‰ 161.4 ± 6.0¢c
Weight, kg 71.2 ± 12.1 64.6 ± 10.9c 75.5 ± 13.0 67.1 ± 11.3c 70.3 ± 12.4 67.6 ± 11.7c
Body mass index, kg/m2 27.0 ± 4.5 25.0 ± 4.0c 28.3 ± 4.9 25.8 ± 4.1 26.7 ± 4.6 25.9 ± 4.2c
FRAX-score, MOF (%) 18.0 ± 7.6 31.5 ± 12.8c 12.4 ± 4.2 25.5 ± 11.6c 14.0 ± 3.3 29.8 ± 11.4c
FRAX-score, HIP (%) 7.2 ± 6.9 17.4 ± 13.6c 3.0 ± 2.8 12.9 ± 11.4c 4.4 ± 2.2 16.0 ± 12.4c
Prior fracture, n (%) 420 (22.4) 680 (61.4)c 111 (19.4) 989 (41.0)c 0 (0) 1100 (64.8)c
Rheumatoid arthritis, n (%) 72 (3.8)† 44 (4.0)¶ 24 (4.2)€ 92 (3.8)ø 36 (2.8)¥ 80 (4.7)Δb
Heredity of hip
fracture, n (%)
305 (16.3) 211 (19.1) 66 (11.5) 450 (18.7)c 51 (4.0) 465 (27.4)c
Excessive alcohol
consumption, n (%)
8 (0.4) 7 (0.6) 4 (0.7) 11 (0.5) 4 (0.3) 11 (0.6)
Current smoker, n (%) 89 (4.7)Ω 65 (5.9) 20 (3.5) 134 (5.6)∞a 53 (4.1)‰ 101 (5.9)a
Glucocorticoid
treatment, n (%)
0 (0.0) 99 (8.9)c 18 (3.1) 81 (3.4) 16 (1.2) 83 (4.9)c
Diabetes, n (%) 210 (11.2) 81 (7.3)c 76 (13.3) 215 (8.9)b 148 (11.5) 143 (8.4)b
Femoral neck aBMD 0.70 ± 0.09 0.59 ± 0.09c 0.82 ± 0.07 0.62 ± 0.08c 0.72 ± 0.10 0.62 ± 0.09c
T-score femoral neck
> −1.0 579 (30.9) 64 (5.8) 549 (96.0) 94 (3.9) 450 (35.0) 193 (11.4)
− 1.0 to − 2.49 1297 (69.1) 602 (54.4) 23 (4.0) 1876 (77.8) 833 (64.8) 1066 (62.8)
≤ − 2.5 0 (0) 441 (39.8) 0 (0) 441 (18.3) 2 (0.2) 439 (25.9)
Use of osteoporotic drug
Bisphosphonates, n (%) 71 (3.8) 215 (19.4) 11 (1.9) 275 (11.4) 49 (17.1) 237 (14.0)
Zoledronic acid, n (%) 4 (0.2) 19 (1.7) 1 (0.2) 22 (0.9) 2 (0.2) 21 (1.2)
Denosumab, n (%) 1 (0.1) 22 (2.0) 0 (0) 23 (1.0) 2 (0.2) 21 (1.2)
Continuous variables are presented by mean ± SD and were compared by independent samples t test. Dichotomous variables are presented as number of
subjects and percentage and differences were analyzed by the chi square test. Excessive alcohol consumption = 21 drinks or more per week.
Glucocorticoid treatment = treatment with 5 mg per oral prednisolone or equal for more than 3 months, diabetes, defined by physician diagnosis
SvOS Swedish osteoporosis society guidelines, NOF National Osteoporosis Foundation, NOGG National Osteoporosis Guideline Group, SD standard
deviation, aBMD areal bone mineral density, FRAX fracture risk assessment tool, MOF major osteoporotic fracture, HIP hip fracture. Each column
presents the maximum number of participants and deviations are denoted for each variable by the following: ∞ = 2410, ø = 2408, $ = 2405, ¢ = 1692,
Ω = 1875, # = 1874, † = 1873, ‰ = 1284, ¥ = 1283, Δ = 1696, ¶ = 1106, £ = 1102, € = 571. A p value below 0.05 was considered significant
a p value < 0.05
b p value < 0.01
c p value < 0.001
1300 Osteoporos Int (2019) 30:1297–1305
variables: body mass index, obesity (BMI of 30 or over), high
blood pressure, prior fracture, and glucocorticoid treatment
(Table 3). The same method was used to evaluate the predic-
tive ability of FRAX-score for either hip or major osteoporotic
fracture independently of other covariates (i.e., level of edu-
cation, living alone, obesity, high blood pressure, and prior
falls). Together with high blood pressure, both hip and major
osteoporotic FRAX-score were associated with receiving os-
teoporosis medication (Table 3).
Discussion
In this study, we report the existence of a large treatment gap
among well characterized elderly Swedish women with a high
fracture risk. Asmany as 1107 (37%)womenwere found to be
eligible for treatment according to SvOS guidelines, but only
21.8% of these women had current or recent osteoporosis
medication. Interestingly, as many as 74 women, not eligible
for treatment according to SvOS guidelines, were treated de-
spite being in the low-risk group. Factors associated with os-
teoporosis treatment were predominantly prior fracture and
oral treatment with glucocorticoids but also high blood pres-
sure, obesity, and body mass index.
The present study was designed to investigate different
lifestyle factors (e.g., smoking, medications, and physical ac-
tivity) and bone phenotypes’ association with incident frac-
tures, therefore the ability to investigate osteoporosis preva-
lence might be limited. With a rather low inclusion rate
(47.4%), which probably has resulted in inclusion of a health-
ier part of the population with a lower fracture risk, these
findings might not be applicable to the general population of
older women. To investigate the potential generalization of
our findings, other clinical markers were used (e.g., blood
pressure). Within this cohort (SUPERB), 1783 women
(59.8%) were hypertensive defined as either having a systolic
Fig. 1 Number of women eligible for treatment according to the Swedish
Osteoporotic Society (SvOS) criteria and the proportions with current or
recent treatment among women eligible for treatment (left panel). To the
right, the type of osteoporosis medication used are presented for the
treated women
Fig. 2 Number and proportions
of women eligible for treatment,
according to the National
Osteoporotic Foundation (NOF)
and National Osteoporosis
Guideline Group (NOGG), and
women with actual current or re-
cent treatment among women eli-
gible for treatment. NOF and
NOGG guidelines = subjects eli-
gible for treatment as a result of
fulfilling any of the NOF or
NOGG treatment criteria,
respectively
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pressure above or equal to 140 mmHg or a diastolic pressure
above or equal to 90 mmHg. The prevalence of hypertension
found in SUPERB corresponds well to earlier presented data
from a large population based study in Sweden, in which in
total 60% of both men and women (age 45–73 years) and 54%
for only women, were diagnosed with hypertension [30]. This
finding indicates that the SUPERB population is representa-
tive of the general population.
Previously performed studies in Europe and in the US have
been based on register data for prevalence of osteoporosis and
osteoporosis medication [10, 11, 31], and were therefore not
able to fully take all relevant clinical risk factors into account.
Being able to take most relevant clinical risk factors into ac-
count, we found in the present study that the treatment gap,
according to NOF guidelines, in our older Swedish women
was similar or somewhat lower than what was previously
reported in older women in the US [19, 20]. With the updated
NOF guidelines [19], Donaldson et al. found that 93%, of the
women aged 75 or older included in the study of osteoporotic
fractures, and Berry et al. found that 86%, of women in the
same age category participating in the Framingham study,
would be eligible for treatment with the incorporation of
FRAX into the NOF guidelines [19, 20]. However, there is a
large variation in fracture risk between different regions of the
world [5]. An Israeli study was able to investigate treatment
eligibility using also common clinical risk factors. The pro-
portion eligible for treatment using NOF guidelines was only
30.5% compared to the 81% rate observed in the present
study. Such difference might be explained by the much higher
fracture risk in Swedish elderly women compared to Israeli
patients, a group consisting both of men and women with a
wide age span from 50 to 90 years of age [32]. The much more
treatment conservative SvOS guidelines identify women eligi-
ble for treatment at higher risk than the NOF andNOGGguide-
lines but result in a lower prevalence of women eligible for
treatment. Thus, interventions in women according to SvOS
vs. NOF or NOGG guidelines will likely result in larger abso-
lute risk reductions in fractures, at the cost of failing to prevent
fractures in women with intermediate risk according to SvOS
guidelines. Based on the numbers of treatment eligible women
Table 2 Characteristics of
women eligible for treatment,
according to SvOS guidelines,
and women not eligible for
treatment
Women eligible for treatment
Variables No osteoporosis
treatment (n = 866)
Osteoporosis
treatment (n = 241)
p
Age, years 78.0 ± 1.64 78.0 ± 1.61 0.93
Height, cm 160.8 ± 6.06# 160.7 ± 6.28€ 0.86
Weight, kg 64.9 ± 10.8 63.7 ± 11.4 0.13
Body mass index, kg/m2 25.1 ± 3.97 24.6 ± 3.98 0.10
Level of education, n (%) 660 (76.2) 194 (80.5) 0.16
Living alone, n (%) 456 (52.7) 129 (53.5) 0.81
Diabetes, n (%) 64 (7.4) 17 (7.1) 0.86
Rheumatoid arthritis, n (%) 37 (4.3)£ 7 (2.9) 0.34
Obesity, n (%) 89 (10.3) 27 (11.2) 0.68
High blood pressure, n (%) 521 (60.2) 120 (49.8) 0.004
Excessive alcohol, n (%) 5 (0.6) 2 (0.8) 0.66
Current smoking, n (%) 49 (5.7) 16 (6.6) 0.57
Previous fall, n (%) 259 (29.9) 87 (36.1) 0.07
Prior fracture, n (%) 345 (39.8) 141 (58.5) < 0.001
Glucocorticoid treatment, n (%) 64 (7.4) 35 (14.5) < 0.001
FRAX-score, MOF (%) 31.0 ± 12.3 33.5 ± 14.1 0.01
FRAX-score, HIP (%) 16.9 ± 13.0 19.0 ± 15.3 0.05
Continuous variables are presented by mean ± SD and were compared by independent samples t test.
Dichotomous variables are presented as number of subjects and percentage and differences were analyzed by
the chi square test. p values below 0.05 was considered significant and are presented in italic numbers. Obesity =
BMI ≥ 30, high blood pressure = either ≥ 90 mmHg diastolic or ≥ 140 mmHg systolic blood pressure, excessive
alcohol = 21 drinks or more per week, previous fall = experienced a fall the last 12 months, prior fracture =
fracture after the age of 50 at all locations except skull, glucocorticoid treatment = treatment with 5 mg per oral
prednisolone or equal for more than 3 months
SvOS Swedish osteoporosis society guidelines, SD standard deviation, FRAX fracture risk assessment tool,MOF
major osteoporotic fracture, HIP hip fracture. Each column presents the maximum number of participants and
deviations are denoted for each variable by the following: £ = 865, # = 862, € = 240
A p value below 0.05 was considered significant
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and the FRAX hip fracture probabilities, the SvOS guidelines
would only identify 193 hip fractures (17.4% FRAX hip frac-
ture probability in 1107 women) while the NOGG guidelines
would identify as many as 272 women with hip fractures
(16.0% FRAX hip fracture probability in 1698 women).
The existing treatment gap has many potential explana-
tions. To be able to increase the proportion of treated patients,
we need a better understanding in which factors that are asso-
ciated with increased probability of receiving osteoporosis
medication. In a large population-based study, women were
divided into high- and low-risk groups and different predictors
of receiving treatment were investigated. For both groups, a
self-reported diagnosis of osteoporosis followed by a self-
reported diagnosis of osteopenia were the strongest predictors
for treatment. In addition, the study looked at the proportion of
treated women for each FRAX variable and compared to
women without and found that women who had the most
included FRAX risk factors were more likely to receive treat-
ment [16]. However, a higher treatment rate in women with a
higher prevalence of FRAX-included risk factors is somewhat
expected. Therefore, we investigated different characteristics
predictive value of receiving osteoporosis medication when
competing with the actual FRAX-score as well as looking at
all characteristics individually in a high-risk population-based
study. Our results demonstrate that important risk factors for
women to receive osteoporosis medication include prior frac-
ture, previous or current treatment with glucocorticoids, and
FRAX-scores for major osteoporotic and hip fracture.
The FRAX-score for a major osteoporotic or hip fracture is
country specific, resulting in men and women, in different
parts of the world (e.g., Sweden and USA), obtaining different
FRAX-scores, even if the same risk factors are present. To
evaluate potential undertreatment of Swedish elderly women
with an American or British treatment definition could be
questioned. The obtained fracture risk for the Swedish elderly
women in the present study would have been lower if they had
been analyzed using the US or UK FRAX calculators.
However, these findings emphasize that an even larger pro-
portion of the included Swedish women would have been
recommended osteoporosis medication, if the lower treatment
thresholds applied by NOF or NOGG would have been used
also in Sweden.
Table 3 Associations between
anthropometrics, clinical risk
factors, and current or recent
osteoporosis treatment in women
eligible for treatment, according
to SvOS guidelines
Variables Crude OR 95% CI p Adjusted OR 95% CI p
Age 1.00 0.91–1.09 0.93 0.99 0.90–1.09 0.81
Height 1.00 1.00–1.00 0.86 1.00 1.00–1.00 0.26
Weight 0.99 0.98–1.00 0.13 1.17 0.96–1.43 0.13
Body mass index 0.97 0.93–1.01 0.10 0.93 0.88–0.98 0.01
Level of education 1.29 0.90–1.84 0.16 1.11 0.76–1.60 0.60
Living alone 1.04 0.78–1.38 0.81 0.99 0.73–1.34 0.94
Diabetes 0.95 0.55–1.66 0.86 0.93 0.52–1.65 0.80
Rheumatoid arthritis 0.67 0.30–1.52 0.34 0.50 0.20–1.25 0.14
Obesity 1.10 0.70–1.74 0.68 2.12 1.10–4.10 0.02
High blood pressure 0.66 0.49–0.88 0.004 0.67 0.50–0.90 0.01
Excessive alcohol 1.44 0.28–7.47 0.66 1.53 0.28–8.45 0.63
Current smoking 1.19 0.66–2.13 0.57 1.21 0.65–2.24 0.54
Previous fall 1.32 0.98–1.79 0.07 1.18 0.86–1.62 0.30
Prior fracture 2.21 1.61–3.06 < 0.001 2.58 1.84–3.61 < 0.001
Glucocorticoid treatment 2.13 1.37–3.30 0.01 2.88 1.80–4.59 < 0.001
FRAX-score
MOF 1.02 1.00–1.03 0.01 1.02 1.00–1.03 0.01
HIP 1.01 1.00–1.02 0.03 1.01 1.00–1.02 0.03
Backward stepwise linear regression was used to investigate the associations between variables and current or
recent osteoporosis treatment. The results are presented as odds ratios (OR) with corresponding 95% confidence
interval (CI) for the final model and the last given result for variables being dropped from the model. The models
investigating FRAX-scores were adjusted for variables not included in the calculation of the investigated score
(i.e., level of education, living alone, obesity, high blood pressure, and previous fall). p values below 0.05 was
considered significant and are presented in italic numbers. Crude = non-adjusted models, adjusted = models
adjusted for all presented variables, obesity = BMI ≥ 30, high blood pressure = above either 90 mmHg diastolic
or 140 mmHg systolic, excessive alcohol = 21 drinks or more per week, previous fall = experienced a fall the last
12 months, prior fracture = fracture after the age of 50 at all locations except skull, glucocorticoid treatment =
treatment with 5 mg per oral prednisolone or equal for more than 3 months
MOF major osteoporotic fracture, HIP hip fracture
A p value below 0.05 was considered significant
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This study has some limitations. Treatment with osteoporo-
sis medication was assessed by questionnaire, which is limited
by the patient’s recollection of treatment. Preferably, treatment
for osteoporosis should have been obtained from the prescrip-
tion registry. The present study was only performed on elderly
women. Therefore, treatment eligibility cannot be presented for
younger postmenopausal women ormen. The FRAX calculator
is a widely used web-based tool for fracture prediction and has
been validated in several large cohorts. However, FRAX has
some limitations, which include the inability to account for,
e.g., falls risk, recency and number of prevalent fractures, dose
of glucocorticoid treatment, alcohol, and smoking.
This study also has strengths. It is a population-based study
in which we had information not only about the participating
women’s skeletal phenotypes but also all other commonly
used risk factors for fracture. Such information enables a com-
prehensive evaluation of fracture risk allowing a well-founded
decision regarding treatment eligibility. The cohort
(SUPERB) has a rather narrow age span (75–80 years), which
enables us to visualize the critical situation close to the dra-
matic exponential increase in hip fracture risk, the fracture
type that results in most patient suffering and highest societal
costs, commonly seen after the age of 80 [33].
The present study is first to report of a substantial treatment
gap in a well-characterized population of older Swedish wom-
en with high fracture risk. The probability to receive osteopo-
rosis medication was higher in women with prior fracture or
previous use of oral glucocorticoids.
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